Roche's (RHHBY) Genentech Receives FDA Breakthrough Therapy Designation for Alecensa in ALK-Positive NSCLC
Tweet Send to a Friend
Genentech, a member of the Roche Group (OTC: RHHBY), announced that it has received a second Breakthrough Therapy Designation (BTD) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
